

Statement of Audited Standalone Financial Results for the Quarter and Year Ended on 31st Mar, 2022


(Rs. in Lacs other than EPS)

		Particulars	Quarter Ended		Year Ended	
			31-03-2022	31-03-2021	31-03-2022	31-03-2021
			Audited	Audited	Audited	Audited
I		Revenue from Operations	2829.01	2955.95	12398.04	10929.42
II		Other Income	127.82	125.98	494.87	430.85
III		Total income (I + II)	2956.83	3081.93	12892.91	11360.27
IV		Expenses				
	(a)	Cost of Materials Consumed	286.16	192.17	1173.86	678.01
	(b)	Purchase of Stock-in-trade	538.66	327.25	2198.08	2013.43
	(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	-90.71	231.97	-228.47	318.39
	(d)	Employee benefit expenses	910.54	790.50	3649.09	3237.71
	(e)	Finance Costs	12.13	12.12	43.45	47.37
	(f)	Depreciation and Amortisation Expense	53.82	52.75	189.87	203.54
	(g)	Other expenses	719.05	911.33	2879.94	2697.65
		Total Expenses (IV)	2429.65	2518.09	9905.82	9196.10
V		Profit before tax (III - IV)	527.18	563.84	2987.09	2164.17
VI		Tax Expense				
	(i)	Current Tax	135.00	179.50	735.00	544.50
	(ii)	Income Tax for previous years	0.00	0.00	-7.21	8.51
	(iii)	Deferred Tax	47.30	-3.33	29.58	-39.08
VII		Profit after tax for the period (V-VI)	344.88	387.67	2229.72	1650.24
VIII		Other Comprehensive Income				
	A (i)	Items that will not be reclassified to profit or loss	47.33	11.04	140.57	219.54
	(ii)	Income Tax relating to Items that will not be reclassified to profit or loss	0.04	-59.07	-10.55	-23.58
	B (i)	Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii)	Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
IX		Total Comprehensive Income for the period (VII + VIII)	392.25	339.64	2359.74	1846.20
X		Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	7.51	8.45	48.58	35.96

Notes:

- The above statement of audited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 27th May, 2022.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures for the quarter ended on 31st March 2022 are the balancing figures between audited figures for the year ended on 31st March 2022 and published year to date figures upto the third quarter ended on 31st December 2021.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with the figures of the current period.
- The Statement of Assets And Liabilities and Cashflow Statement as at 31st March, 2022 are annexed as Annexure A & B respectively.

For Jenburkt Pharmaceuticals Ltd.


 (Ashish U. Bhuta)
 Chairman & Managing Director

 Place : Mumbai
 Date : 27th May 2022

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Annexure - A
Statement of Standalone Assets & Liabilities

			Rs in Lacs	
		Particulars	31/03/2022	31/03/2021
			Amount	Amount
		ASSETS		
(1)		Non-current Assets		
	(a)	Property, Plants & Equipments	995.36	850.69
	(b)	Right to Use Asset	113.94	156.22
	(c)	Goodwill	-	0.14
	(d)	Other Intangible assets	30.57	47.96
	(e)	Capital Work In Progress	21.17	37.76
	(f)	Financial Assets		
	(i)	Investments	796.12	650.07
	(ii)	Loans	13.28	8.14
	(iii)	Other Financial Assets	3,566.00	2,285.78
		Deferred Tax Asset	37.11	73.74
	(g)	Other Non-current Assets	1,130.97	9.10
(2)		Current assets		
	(a)	Inventories	988.77	758.15
	(b)	Financial Assets		
	(i)	Investments	-	25.22
	(ii)	Trade Receivables	1,520.68	1,400.07
	(iii)	Cash and Cash Equivalents	503.13	249.37
	(iv)	Bank Balance other than (iii)	4,399.18	5,401.31
	(v)	Loans	18.97	11.15
	(vi)	Other Financial Assets	27.40	29.95
	(c)	Other Current Assets	109.70	116.92
		Current Tax Asset (Net)	22.58	6.57
		Total Assets	14,294.91	12,118.31
		EQUITY AND LIABILITIES		
(1)		Equity		
	(a)	Equity Share Capital	458.94	458.94
	(b)	Other Equity - Reserves & Surplus	11,279.31	9,387.69
		LIABILITIES		
(2)		Non-current liabilities		
	(a)	Financial Liabilities		
	(i)	Lease Liabilities	48.86	93.97
	(ii)	Other Financial Liabilities	294.25	296.47
	(b)	Deferred Tax Liability	85.57	82.06
(3)		Current Liabilities		
	(a)	Financial Liabilities		
	(i)	Lease Liabilities	45.11	41.66
	(ii)	Borrowings	581.53	371.06
	(iii)	Trade Payables		
	(A)	Total Outstanding dues of Micro Enterprises and Small Enterprises; and	24.71	2.66
	(B)	Total Outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	686.33	456.58
	(iv)	Other Financial Liabilities	555.52	552.94
	(b)	Other Current Liabilities	201.15	227.02
	(c)	Provisions	25.93	127.29
	(d)	Current Tax Liabilities (Net)	7.70	19.98
		Total Equity and Liabilities	14,294.91	12,118.31

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai

Date : 27th May, 2022

Annexure - B
Cashflow Statement as on 31st March, 2022



Rs in Lacs

		31-03-2022	31-03-2021
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a	Net Profit After Tax	2,229.72	1,650.24
	Adjustments for :		
i	Depreciation and Amortisation Expense	189.86	203.54
	Profit on sale/written off of property, plant and equipment and intangible assets, net	(3.33)	(0.17)
iii	Tax Expense	757.37	513.93
iv	Finance Cost	43.44	47.37
v	Interest Income	(437.13)	(405.26)
vi	Dividend income	(3.28)	(1.82)
vii	Gain on sale of Investment (Short/Long Term Capital Gain)	(0.21)	(0.08)
viii	Provision/write off for doubtful trade receivables/advances	8.37	19.20
ix	Net unrealised foreign exchange gain	(24.45)	(22.21)
x	Others	1.92	(0.69)
	Operating profit (Loss) before working capital changes	2,762.29	2,004.05
b	MOVEMENTS IN WORKING CAPITAL		
i	Increase or (Decrease) in Inventories	(230.62)	331.72
ii	Increase or (Decrease) in Trade Receivables	(104.52)	363.70
iii	Increase or (Decrease) in Other (Current & Non Current) Assets	(1,114.01)	(11.11)
iv	Increase or (Decrease) in Trade Payables	251.79	(161.42)
v	Increase or (Decrease) in Bank Borrowings	210.46	27.17
vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	(25.49)	92.08
vii	Increase or (Decrease) in Provisions	(53.73)	(117.07)
c	Cash used in operation	1,696.17	2,529.12
i	Income Taxes paid (Net of Refund)	(756.07)	(583.65)
	Net cash used in operating activities (A)	940.10	1,945.48
B.	CASH FLOW FROM INVESTING ACTIVITIES :		
i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	(305.43)	(114.51)
ii	Proceeds from disposal of property, plant and equipment and intangible assets	50.64	2.97
iii	Purchase of Investments	(48.44)	(93.28)
iv	Proceeds from Sale / Redemption of Investments	20.76	72.06
v	Other Bank balances not considered as cash and cash equivalents		
	Bank Fixed Deposit made during the year	(12,952.19)	(10,909.16)
	Bank Fixed Deposit matured during the year	12,606.89	8,782.59
vi	Current & Non Current Financial Loans		
	Loan given to Employees	(74.26)	(44.81)
	Loan recovered from Employees	61.31	54.34
vii	Interest Received	504.26	369.88
viii	Dividend Received	3.28	1.82
	Net cash generated by investing activities (B)	(133.19)	(1,878.10)
C.	CASH FLOW FROM FINANCING ACTIVITIES :		
i	Finance Cost	(34.10)	(34.83)
ii	Dividend paid	(468.04)	14.42
iii	Repayment of Lease Liabilities	(51.00)	(51.00)
	Net cash used in financing activities (C)	(553.14)	(71.41)
	NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	253.76	(4.03)
	Cash and cash equivalent at the beginning of the year (1st April, 2021)	249.37	253.40
	Cash and cash equivalent as at the end of the year (31st March, 2022)	503.13	249.37
		253.76	(4.03)

By order of the Board
For Jenburkt Pharmaceuticals Ltd.

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai
Date : 27th May, 2022